Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
The company is also developing V2ACT Immunotherapy for treating pancreatic cancer.
Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate.
The company was incorporated in 2001 and is headquartered in Westlake Village, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.25 Increased by +52.34% | -0.23 Decreased by -9.83% |
| Mar 29, 24 | -0.25 Decreased by -108.33% | -0.19 Decreased by -31.58% |
| Nov 14, 23 | -0.20 Decreased by -66.67% | -0.18 Decreased by -11.11% |
| Aug 14, 23 | -0.23 Decreased by -43.75% | -0.15 Decreased by -53.33% |
| May 15, 23 | -0.53 | -0.16 Decreased by -231.25% |
| Mar 29, 23 | -0.12 | - |
| Sep 19, 22 | -0.12 | - |
| Jun 24, 22 | -0.16 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 8.00 K Decreased by -95.29% | -7.85 M Increased by +45.52% | Decreased by -98.13 K% Decreased by -1.06 K% |
| Dec 31, 23 | 1.46 M Increased by +2.05 K% | -6.77 M Decreased by -108.15% | Decreased by -462.23% Increased by +90.33% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -5.34 M Decreased by -208.88% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -5.82 M Decreased by -104.89% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 170.00 K Increased by +N/A% | -14.41 M Decreased by -248.21% | Decreased by -8.48 K% Decreased by N/A% |
| Dec 31, 22 | 68.00 K Increased by +N/A% | -3.25 M Increased by +13.07% | Decreased by -4.78 K% Decreased by N/A% |
| Sep 30, 22 | 11.00 M Increased by +N/A% | 4.91 M Increased by +266.75% | Increased by +44.63% - |
| Jun 30, 22 | 0.00 Decreased by N/A% | -2.84 M Increased by +57.57% | Decreased by N/A% - |